ASCO, Author Interviews, Cancer Research, Radiation Therapy / 13.06.2018
Radionuclide 177Lu-Dotatate Improves QoL in Patients with Neuroendocrine Tumors
MedicalResearch.com Interview with:
[caption id="attachment_42379" align="alignleft" width="150"]
Dr. Strosberg[/caption]
Jonathan Strosberg MD
Moffitt Cancer Center, Tampa, FL
MedicalResearch.com: What is the background for this study?
Response: Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life. We assessed the impact of 177Lu-Dotatate treatment on time to deterioration in health-related quality of life in patients with advanced midgut neuroendocrine tumors in the NETTER-1 study.
Dr. Strosberg[/caption]
Jonathan Strosberg MD
Moffitt Cancer Center, Tampa, FL
MedicalResearch.com: What is the background for this study?
Response: Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life. We assessed the impact of 177Lu-Dotatate treatment on time to deterioration in health-related quality of life in patients with advanced midgut neuroendocrine tumors in the NETTER-1 study.